Perrigo leverages its scale in store-brand manufacturing to compete with major branded OTC players while building a portfolio of proprietary consumer health brands. The company's competitive advantage lies in its manufacturing efficiency, retail relationships, and ability to deliver quality products at accessible price points across multiple therapeutic categories.
Cyborg Score Rationale
Perrigo operates in a stable consumer healthcare market with recurring demand for OTC products. However, the company faces margin pressures from retail consolidation, private-label competition, and input cost volatility. Its strong market position in store-brand OTC provides defensive cash flows.
Top Insights
Perrigo is the world's largest manufacturer of store-brand OTC medications and supplements, giving it significant negotiating power with major retailers
The company has shifted toward building proprietary consumer brands to reduce dependence on store-brand private label business
Key markets include pain relief, cold and allergy, digestive health, and vitamin supplements across North America and international markets
Perrigo maintains a diversified customer base with exposure to major retail chains, which provides stability but also concentration risk
Named Competitors
Advil, Tylenol, other OTC brands — Major branded OTC pharmaceutical competitors
Arm & Hammer, personal care brands — Diversified consumer health competitor
Private label/store brands — Direct retail brand competition
Recent Developments
(2025) Portfolio rationalization and focus on higher-margin branded products
(2025) Continued investment in digital consumer engagement and e-commerce channels
(2024) Strategic partnerships to expand presence in emerging consumer health categories
Open the full interactive Perrigo report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.